Ruth Harman
PhD
Operations Manager - Oncology Clinical Trials Office (OCTO)
I joined the Oncology Clinical Trials Office (OCTO) as a Trial Manager in May 2019. Prior to this I was a Research Administrator for the HOME Study in the University’s Department of Psychiatry.
I have worked on a number of OCTO trials, including:
ARCADIAN – a phase I trial to assess the safety of combining the drug atovaquone with concurrent chemoradiotherapy in locally advanced Non-Small Cell Lung Cancer.
ATOM – A pre-operative window of opportunity study of the effects of atovaquone on hypoxia in non-small cell lung carcinoma.
CHARIOT – A phase I dose escalation safety trial combining the ATR inhibitor M6620 with chemoradiotherapy in oesophageal cancer and other solid cancers using time to event continual reassessment method.
CYTOFLOC – A trial to investigate the safety and tolerability of a non-endoscopic device called a CytospongeTM for post-chemoradiotherapy surveillance of oesophageal cancer patients .
Information on other OCTO trials can be found here.
Recent publications
-
CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.
Javed SR. et al, (2024), Br J Cancer, 130, 467 - 475
-
Use of a non-endoscopic immunocytological device (Cytosponge™) for post chemoradiotherapy surveillance in patients with oesophageal cancer in the UK (CYTOFLOC): A multicentre feasibility study.
Jones CM. et al, (2022), EClinicalMedicine, 53